References
- Holm-Nielsen P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Path Microbiol Scand 1953; 33: 10–21
- White M J, Miller F N, Heuser L S, Pietsch C G. Human malignant ascites and histamine-induced protein leakage from the normal microcirculation. Microvasc Res 1988; 35: 63–72
- Garrison R L, Kaelin L D, Heuser L S, Galloway R H. Malignant ascites: clinical and experimental observations. Ann Surg 1986; 203: 644–51
- Tomb J. A cytopathological study on serous fluid in cancer. J Med Liban 1974; 27: 51–8
- Lu C-W, Wang S-S, Lee S-D, et al. Ascitic fluid analysis in peritoneal carcinomatosis: comparison of various biochemical tests with ascitic cirrhotics. Chin Med J 1991; 47: 350–6
- Prieto M, Gomez-Lechon M J, Hoyos M, Castell J V, Carrasco D, Berenguer J. Diagnosis of malignant ascites: comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference. Dig Dis Sci 1988; 33: 833–8
- Adamsen S, Jönsson P, Brodin B, Lindberg B, Jorpes P. Measurement of fibronectin concentration in benign and malignant ascites. Eur J Surg 1991; 157: 325–8
- Siddiqui R A, Kochhar R, Singh V, Rajwanshi A, Goenka M K, Mehta S K. Evaluation of fibronectin as a marker of malignant ascites. J Gastroenterol Hepatol 1992; 7: 161–4
- Erdös E G. Commentary. The kinins. A status report. Biochem Pharmacol 1976; 25: 1563–9
- Colman R W, Schmaier A H. The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. CRC Crit Rev Oncol Hematol 1986; 5: 57–85
- Kluft C, Dooijewaard G, Emeis J J. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50–68
- Colman R W. Surface-mediated defence reactions. The plasma contact activation system. J Clin Invest 1984; 73: 1249–53
- Schapira M, Scott C F, Colman R W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462–8
- Schapira M. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemost 1987; 13: 69–78
- Karlsrud T S, Buø L, Aasen A O, Johansen H T. Characterization of kininogens in human malignant ascites. Thromb Res 1991; 63: 641–50
- Buø L, Karlsrud T S, Johansen H T, Aasen A O. The contact system in human malignant and benign ascites. Scand J Clin Lab Invest 1993; 53: 117–24
- Røise O, Sivertsen S, Ruud T E, Bouma B N, Stadaas J O, Aasen A O. Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer 1990; 65: 1355–9
- Kingsley G R. The determination of serum total protein, albumin, and globulin by the biuret reaction. J Biol Chem 1939; 131: 197–200
- Aasen A O, Kierulf P, Strømme J. Methodological considerations on chromogenic peptide substrate assays and application on automated analyzers. Acta Chir Scand 1982; 509(Suppl)17–22
- Laurell C B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45–52
- Galen R S, Gambino S R. Beyond normality: the predictive value and efficiency of medical diagnosis. John Wiley, New York 1975
- Sackett D L, Haynes R B, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. Little, Brown & Co., Boston 1985
- Villamil F G, Sorroche P B, Aziz H F, Lopez P M, Oyhamburu J M. Ascitic fluid α1-antitrypsin. Dig Dis Sci 1990; 35: 1105–9
- Colli A, Buccino G, Cocciolo M, Parravicini R, Mariani F, Scattrini G. Diagnostic accuracy of fibronectin in the differential diagnosis of ascites. Cancer 1986; 58: 2489–93
- Harris C C, Primack A, Cohen M. Elevated α1-antitrypsin serum levels in lung cancer patients. Cancer 1974; 34: 280–1
- Chio L F, Oon C J. Changes in serum α1-antitrypsin, α1-acid glycoprotein, β2-glycoprotein 1 in patients with malignant hepatocellular carcinoma. Cancer 1979; 43: 596–604